<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32924089</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1534-6307</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>22</Volume>
            <Issue>10</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Sep</Month>
              <Day>13</Day>
            </PubDate>
          </JournalIssue>
          <Title>Current rheumatology reports</Title>
          <ISOAbbreviation>Curr Rheumatol Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Kawasaki Disease: an Update.</ArticleTitle>
        <Pagination>
          <StartPage>75</StartPage>
          <MedlinePgn>75</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">75</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s11926-020-00941-4</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE OF REVIEW">Provide the most recent updates on the epidemiology, pathogenesis, and treatment advances in Kawasaki disease.</AbstractText>
          <AbstractText Label="RECENT FINDINGS">Treatment advances in complex, IVIG-refractory cases of Kawasaki disease. Multisystem inflammatory syndrome, a newly reported inflammatory condition with Kawasaki-like features and an association with the 2019 Coronavirus (COVID-19). Kawasaki disease (KD) is a rare systemic inflammatory disease that predominately affects children less than 5 years of age. Pathogenesis of KD remains unknown; the leading theory is that an unknown stimulus triggers an immune-mediated inflammatory cascade in a genetically susceptible child. Classic KD is a clinical diagnosis based on set criteria and excluding other similar clinical entities. Patients who do not fulfill complete diagnostic criteria for KD are often referred to as atypical (or incomplete) KD. The most feared complication of KD is coronary artery abnormality development, and patients with atypical KD are also at risk. Administration of intravenous immunoglobulin (IVIG) and aspirin has greatly reduced the incidence of coronary lesions in affected children. Several other immune-modulating therapies have recently been utilized in complex or refractory cases.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rife</LastName>
            <ForeName>Eileen</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Louisiana State University, New Orleans, LA, USA. erife@lsuhsc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gedalia</LastName>
            <ForeName>Abraham</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pediatric Rheumatology, Children's Hospital and LSU Health Sciences Center, 2000 Henry Clay Avenue, New Orleans, LA, 70118, USA. AGedal@lsuhsc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>09</Month>
          <Day>13</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Curr Rheumatol Rep</MedlineTA>
        <NlmUniqueID>100888970</NlmUniqueID>
        <ISSNLinking>1523-3774</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003952" MajorTopicYN="N">Diagnostic Imaging</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009080" MajorTopicYN="N">Mucocutaneous Lymph Node Syndrome</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Kawasaki diagnosis</Keyword>
        <Keyword MajorTopicYN="Y">Kawasaki differential</Keyword>
        <Keyword MajorTopicYN="Y">Kawasaki disease</Keyword>
        <Keyword MajorTopicYN="Y">Kawasaki review</Keyword>
        <Keyword MajorTopicYN="Y">Kawasaki treatment</Keyword>
        <Keyword MajorTopicYN="Y">Kawasaki workup</Keyword>
        <Keyword MajorTopicYN="Y">Kawasaki-like disease</Keyword>
        <Keyword MajorTopicYN="Y">Multi system inflammatory syndrome</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>14</Day>
          <Hour>5</Hour>
          <Minute>58</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>9</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32924089</ArticleId>
        <ArticleId IdType="pmc">PMC7487199</ArticleId>
        <ArticleId IdType="doi">10.1007/s11926-020-00941-4</ArticleId>
        <ArticleId IdType="pii">10.1007/s11926-020-00941-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Makino N, Nakamura Y, Yashiro M, Kosami K, et al.  The Nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016. Pediatr Int. 2019;61(4):397–403. doi: 10.1111/ped.13809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ped.13809</ArticleId>
            <ArticleId IdType="pubmed">30786118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Makino N, Nakamura Y, Yashiro M, Ae R, Tsuboi S, Aoyama Y, Kojo T, Uehara R, Kotani K, Yanagawa H. Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012: from the results of the 22nd nationwide survey. J Epidemiol. 2015;25(3):239–245. doi: 10.2188/jea.JE20140089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2188/jea.JE20140089</ArticleId>
            <ArticleId IdType="pmc">PMC4341001</ArticleId>
            <ArticleId IdType="pubmed">25716368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maddox RA, Person MK, Lindsay JL, Baherling DL, et al. Abstract 0.03: Monitoring the occurrence of Kawasaki syndrome in the United States. Circulation. Abstracts from the Eleventh International Kawasaki Disease Symposium. 2015;131(suppl_2).</Citation>
        </Reference>
        <Reference>
          <Citation>Holman RC, Christensen KY, Belay ED, Steiner CA, Effler PV, Miyamura J, Forbes S, Schonberger LB, Melish M. Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. Hawaii Med J. 2010;69:194–197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3118023</ArticleId>
            <ArticleId IdType="pubmed">20845285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bell DM, Morens DM, Holman RC, Hurwitz ES, Hunter MK. Kawasaki syndrome in the United States: 1976 to 1980. Am J Dis Child. 1983;137(3):211–214. doi: 10.1001/archpedi.1983.02140290003001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archpedi.1983.02140290003001</ArticleId>
            <ArticleId IdType="pubmed">6823918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holman RC, Christensen KY, Belay ED, et al.  Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. Hawaii Med J. 2010;69(8):194–197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3118023</ArticleId>
            <ArticleId IdType="pubmed">20845285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fujita Y, Nakamura Y, Sakata K, Hara N, Kobayashi M, Nagai M, Yanagawa H, Kawasaki T. Kawasaki disease in families. Pediatrics. 1989;84:666–669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2780128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kottek A, Shimizu C, Burns JC. Kawasaki disease in monozygotic twins. Pediatr Infect Dis J. 2011;30(12):1114–1116. doi: 10.1097/INF.0b013e31822ac4ff.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/INF.0b013e31822ac4ff</ArticleId>
            <ArticleId IdType="pmc">PMC3222730</ArticleId>
            <ArticleId IdType="pubmed">21796015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harada F, Sada M, Kamiya T, Yanase Y, Kawasaki T, Sasazuki T. Genetic analysis of Kawasaki syndrome. Am J Hum Genet. 1986;39(4):537–539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1683975</ArticleId>
            <ArticleId IdType="pubmed">3766546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uehara R, Yashiro M, Nakamura Y, Yanagawa H. Kawasaki disease in parents and children. Acta Paediatr. 2003;92:694–697. doi: 10.1111/j.1651-2227.2003.tb00602.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1651-2227.2003.tb00602.x</ArticleId>
            <ArticleId IdType="pubmed">12856980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dergun M, Kao A, Hauger SB, Newburger JW, Burns JC. Familial occurrence of Kawasaki syndrome in North America. Arch Pediatr Adolesc Med. 2005;159(9):876–881. doi: 10.1001/archpedi.159.9.876.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archpedi.159.9.876</ArticleId>
            <ArticleId IdType="pmc">PMC2910318</ArticleId>
            <ArticleId IdType="pubmed">16143748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uehara R, Yashiro M, Nakamura Y, Yanagawa H. Clinical features of patients with Kawasaki disease whose parents had the same disease. Arch Pediatr Adolesc Med. 2004;158:1166–1169. doi: 10.1001/archpedi.158.12.1166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archpedi.158.12.1166</ArticleId>
            <ArticleId IdType="pubmed">15583102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onouchi Y, Ozaki K, Buns JC, Shimizu C, Hamada H, Honda T, Terai M, Honda A, Takeuchi T, Shibuta S, Suenaga T, Suzuki H, Higashi K, Yasukawa K, Suzuki Y, Sasago K, Kemmotsu Y, Takatsuki S, Saji T, Yoshikawa T, Nagai T, Hamamoto K, Kishi F, Ouchi K, Sato Y, Newburger JW, Baker AL, Shulman ST, Rowley AH, Yashiro M, Nakamura Y, Wakui K, Fukushima Y, Fujino A, Tsunoda T, Kawasaki T, Hata A, Nakamura Y, Tanaka T. Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum Mol Genet. 2010;19(14):2898–2906. doi: 10.1093/hmg/ddq176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddq176</ArticleId>
            <ArticleId IdType="pmc">PMC2893807</ArticleId>
            <ArticleId IdType="pubmed">20423928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onouchi Y, Ozaki K, Burns JC, et al.  A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet. 2012;44(5):517–521. doi: 10.1038/ng.2220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.2220</ArticleId>
            <ArticleId IdType="pubmed">22446962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, Nakamura Y, Yanagawa H, Wakui K, Fukushima Y, Kishi F, Hamamoto K, Terai M, Sato Y, Ouchi K, Saji T, Nariai A, Kaburagi Y, Yoshikawa T, Suzuki K, Tanaka T, Nagai T, Cho H, Fujino A, Sekine A, Nakamichi R, Tsunoda T, Kawasaki T, Nakamura Y, Hata A. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008;40(1):35–42. doi: 10.1038/ng.2007.59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.2007.59</ArticleId>
            <ArticleId IdType="pmc">PMC2876982</ArticleId>
            <ArticleId IdType="pubmed">18084290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Onouchi Y. Genetics of Kawasaki disease: what we know and don’t know. Circ J. 2012;76(7):1581–1586. doi: 10.1253/circj.cj-12-0568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1253/circj.cj-12-0568</ArticleId>
            <ArticleId IdType="pubmed">22789975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abrams JY, Weintraub ES, Baggs JM, McCarthy NL, Schonberger LB, Lee GM, Klein NP, Belongia EA, Jackson ML, Naleway AL, Nordin JD, Hambidge SJ, Belay ED. Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006. Vaccine. 2015;33(2):382–387. doi: 10.1016/j.vaccine.2014.10.044.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2014.10.044</ArticleId>
            <ArticleId IdType="pubmed">25444786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker MA, Baer B, Kulldorff M, Zichittella L, Reindel R, DeLuccia S, Lipowicz H, Freitas K, Jin R, Yih WK. Kawasaki disease and 13-valent pneumococcal conjugate vaccination among young children: a self-controlled risk interval and cohort study with null results. PLoS Med. 2019;16(7):e1002844. doi: 10.1371/journal.pmed.1002844.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pmed.1002844</ArticleId>
            <ArticleId IdType="pmc">PMC6605647</ArticleId>
            <ArticleId IdType="pubmed">31265459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall GC, Tulloh RM, Tulloh LE. The incidence of Kawasaki disease after vaccination within the UK pre-school National Immunisation Programme: an observational THIN database study. Pharmacoepidemiol Drug Saf. 2016;25(11):1331–1336. doi: 10.1002/pds.4108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pds.4108</ArticleId>
            <ArticleId IdType="pubmed">27651105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>L'Huillier AG, Brito F, Wagner N, Cordey S, Zdobnov E, Posfay-Barbe KM, Kaiser L. Identification of viral signatures using high-throughput sequencing on blood of patients with Kawasaki disease. Front Pediatr. 2019;7:524. doi: 10.3389/fped.2019.00524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fped.2019.00524</ArticleId>
            <ArticleId IdType="pmc">PMC6930886</ArticleId>
            <ArticleId IdType="pubmed">31921732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burns JC, Herzog L, Fabri O, Tremoulet AH, Rodó X, Uehara R, Burgner D, Bainto E, Pierce D, Tyree M, Cayan D, for the Kawasaki Disease Global Climate Consortium  Seasonality of Kawasaki disease: a global perspective. PLoS One. 2013;8(9):e74529. doi: 10.1371/journal.pone.0074529.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0074529</ArticleId>
            <ArticleId IdType="pmc">PMC3776809</ArticleId>
            <ArticleId IdType="pubmed">24058585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol. 2012;22(2):79–85. doi: 10.2188/jea.je20110131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2188/jea.je20110131</ArticleId>
            <ArticleId IdType="pmc">PMC3798585</ArticleId>
            <ArticleId IdType="pubmed">22307434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodó X, Ballester J, Cayan D, Melish ME, Nakamura Y, Uehara R, Burns JC. Association of Kawasaki disease with tropospheric wind patterns. Sci Rep. 2011;1:152. doi: 10.1038/srep00152.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep00152</ArticleId>
            <ArticleId IdType="pmc">PMC3240972</ArticleId>
            <ArticleId IdType="pubmed">22355668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodó X, Curcoll R, Robinson M, et al.  Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. Proc Natl Acad Sci U S A. 2014;111(22):7952–7957. doi: 10.1073/pnas.1400380111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1400380111</ArticleId>
            <ArticleId IdType="pmc">PMC4050536</ArticleId>
            <ArticleId IdType="pubmed">24843117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jorquera H, Borzutzky A, Hoyos-Bachiloglu R, García A. Association of Kawasaki disease with tropospheric winds in Central Chile: is wind-borne desert dust a risk factor? Environ Int. 2015;78:32–38. doi: 10.1016/j.envint.2015.02.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.envint.2015.02.007</ArticleId>
            <ArticleId IdType="pubmed">25743034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaggi P, Kajon AE, Mejias A, Ramilo O, Leber A. Human adenovirus infection in Kawasaki disease: a confounding bystander? Clin Infect Dis. 2013;56(1):58–64. doi: 10.1093/cid/cis807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/cis807</ArticleId>
            <ArticleId IdType="pmc">PMC3732045</ArticleId>
            <ArticleId IdType="pubmed">23011145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gedalia A. Kawasaki disease: 40 years after the original report. Curr Rheumatol Rep. 2007;9(4):336–341. doi: 10.1007/s11926-007-0053-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11926-007-0053-7</ArticleId>
            <ArticleId IdType="pmc">PMC7089469</ArticleId>
            <ArticleId IdType="pubmed">17688844</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alphonse MP, Duong TT, Shumitzu C, Hoang TL, McCrindle BW, Franco A, Schurmans S, Philpott DJ, Hibberd ML, Burns J, Kuijpers TW, Yeung RSM. Inositol-triphosphate 3-kinase C mediates inflammasome activation and treatment response in Kawasaki disease. J Immunol. 2016;197(9):3481–3489. doi: 10.4049/jimmunol.1600388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1600388</ArticleId>
            <ArticleId IdType="pubmed">27694492</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anzai F, Watanabe S, Kimura H, Kamata R, Karasawa T, Komada T, Nakamura J, Nagi-miura N, Ohno N, Takeishi Y, Takahashi M. Crucial role of NLRP3 inflammasome in a murine model of Kawasaki disease. J Mol Cell Cardiol. 2020;138:185–196. doi: 10.1016/j.yjmcc.2019.11.158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yjmcc.2019.11.158</ArticleId>
            <ArticleId IdType="pubmed">31836541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477–489. doi: 10.1038/s41577-019-0165-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-019-0165-0</ArticleId>
            <ArticleId IdType="pmc">PMC7807242</ArticleId>
            <ArticleId IdType="pubmed">31036962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franco A, Shimizu C, Tremoulet AH, Burns JC. Memory T-cells and characterization of peripheral T-cell clones in acute Kawasaki disease. Autoimmunity. 2010;43(4):317–324. doi: 10.3109/08916930903405891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08916930903405891</ArticleId>
            <ArticleId IdType="pmc">PMC2871072</ArticleId>
            <ArticleId IdType="pubmed">20166878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowley AH, Eckerley CA, Jäck HM, Shulman ST, Baker SC. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol. 1997;159(12):5946–5955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9550392</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowley AH, Shulman ST, Mask CA, Finn LS, Terai M, Baker SC, Galliani CA, Takahashi K, Naoe S, Kalelkar MB, Crawford SE. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J Infect Dis. 2000;182(4):1183–1191. doi: 10.1086/315832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/315832</ArticleId>
            <ArticleId IdType="pubmed">10979916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindquist ME, Hicar MD. B cells and antibodies in Kawasaki disease. Int J Mol Sci. 2019;20(8):1834. doi: 10.3390/ijms20081834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ijms20081834</ArticleId>
            <ArticleId IdType="pmc">PMC6514959</ArticleId>
            <ArticleId IdType="pubmed">31013925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franco A, Touma R, Song Y, Shimizu C, Tremoulet AH, Kanegaye JT, Burns JC. Specificity of regulatory T cells that modulate vascular inflammation. Autoimmunity. 2014;47(2):95–104. doi: 10.3109/08916934.2013.860524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08916934.2013.860524</ArticleId>
            <ArticleId IdType="pubmed">24490882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doi M, Takeda T, Sakurai Y, et al.  Altered immunoglobulin A and M levels associated with changes in BAFF and APRIL after administration of intravenous immunoglobulin to treat Kawasaki disease. J Investig Allergol Clin Immunol. 2010;20(5):413–418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20945608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ha KS, Jang G, Lee J, Lee KC, Hong YS, Son CS, Lee JW. Incomplete clinical manifestation as a risk factor for coronary artery abnormalities in Kawasaki disease: a meta-analysis. Eur J Pediatr. 2013;172(3):343–349. doi: 10.1007/s00431-012-1891-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00431-012-1891-5</ArticleId>
            <ArticleId IdType="pubmed">23229186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>• McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association [published correction appears in circulation. 2019 Jul 30;140(5):e181-e184]. Circulation. 2017;135(17):e927-e999. 10.1161/CIR.0000000000000484The most recent evidence-based guidance for healthcare professionals who manage Kawasaki disease. A comprehensive resource.</Citation>
        </Reference>
        <Reference>
          <Citation>Yanagawa H, Nakamura Y, Yashiro M, Ojima T, Tanihara S, Oki I, Zhang T. Results of the nationwide epidemiologic survey of Kawasaki disease in 1995 and 1996 in Japan. Pediatrics. 1998;102(6):E65. doi: 10.1542/peds.102.6.e65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.102.6.e65</ArticleId>
            <ArticleId IdType="pubmed">9832593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maddox RA, Holman RC, Uehara R, Callinan LS, Guest JL, Schonberger LB, Nakamura Y, Yashiro M, Belay ED. Recurrent Kawasaki disease: USA and Japan. Pediatr Int. 2015;57(6):1116–1120. doi: 10.1111/ped.12733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ped.12733</ArticleId>
            <ArticleId IdType="pmc">PMC4676732</ArticleId>
            <ArticleId IdType="pubmed">26096590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kil HR, Yu JW, Lee SC, Rhim JW, Lee KY. Changes in clinical and laboratory features of Kawasaki disease noted over time in Daejeon, Korea. Pediatr Rheumatol Online J. 2017;15(1):60. doi: 10.1186/s12969-017-0192-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12969-017-0192-y</ArticleId>
            <ArticleId IdType="pmc">PMC5545846</ArticleId>
            <ArticleId IdType="pubmed">28784161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tremoulet AH, Jain S, Chandrasekar D, Sun X, Sato Y, Burns JC. Evolution of laboratory values in patients with Kawasaki disease. Pediatr Infect Dis J. 2011;30(12):1022–6. 10.1097/INF.0b013e31822d4f56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3222731</ArticleId>
            <ArticleId IdType="pubmed">21817952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eladawy M, Dominguez SR, Anderson MS, Glodé MP. Abnormal liver panel in acute Kawasaki disease. Pediatr Infect Dis J. 2011;30(2):141–144. doi: 10.1097/INF.0b013e3181f6fe2a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/INF.0b013e3181f6fe2a</ArticleId>
            <ArticleId IdType="pmc">PMC3096016</ArticleId>
            <ArticleId IdType="pubmed">20861758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shike H, Kanegaye JT, Best BM, Pancheri J, Burns JC. Pyuria associated with acute Kawasaki disease and fever from other causes. Pediatr Infect Dis J. 2009;28(5):440–443. doi: 10.1097/INF.0b013e318193ec8e.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/INF.0b013e318193ec8e</ArticleId>
            <ArticleId IdType="pmc">PMC2738928</ArticleId>
            <ArticleId IdType="pubmed">19319019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwon H, Lee JH, Jung JY, Kwak YH, Kim DK, Jung JH, Chang I, Kim K. N-terminal pro-brain natriuretic peptide can be an adjunctive diagnostic marker of hyper-acute phase of Kawasaki disease. Eur J Pediatr. 2016;175(12):1997–2003. doi: 10.1007/s00431-016-27983.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00431-016-27983</ArticleId>
            <ArticleId IdType="pubmed">27798729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dahdah N, Siles A, Fournier A, Cousineau J, Delvin E, Saint-Cyr C, Spiegelblatt L, Bonny Y, Vartian M, Montigny M. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol. 2009;30(6):810–817. doi: 10.1007/s00246-009-9441-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00246-009-9441-2</ArticleId>
            <ArticleId IdType="pubmed">19365652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin KH, Chang SS, Yu CW, Lin SC, Liu SC, Chao HY, Lee MTG, Wu JY, Lee CC. Usefulness of natriuretic peptide for the diagnosis of Kawasaki disease: a systematic review and meta-analysis. BMJ Open. 2015;5(4):e006703. doi: 10.1136/bmjopen-2014-006703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2014-006703</ArticleId>
            <ArticleId IdType="pmc">PMC4401842</ArticleId>
            <ArticleId IdType="pubmed">25872939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>• Yi L, Zhang J, Zhong J, Zheng Y. Elevated levels of platelet activating factor and its acetylhydrolase indicate high risk of Kawasaki disease. J Interferon Cytokine Res. 2019;40(3). 10.1089/jir.2019.0141A novel new test that may be utilized in the future to help predict Kawasaki disease during the acute phase. More studies need to be conducted prior to its routine use in clinical practice.</Citation>
        </Reference>
        <Reference>
          <Citation>Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, Kazue T, Eto G, Yamakawa R. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996;94(6):1379–1385. doi: 10.1161/01.cir.94.6.1379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.cir.94.6.1379</ArticleId>
            <ArticleId IdType="pubmed">8822996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Research Committee on Kawasaki Disease  . Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. Tokyo: Japanese Ministry of Health and Welfare; 1984. </Citation>
        </Reference>
        <Reference>
          <Citation>Kavey RE, Allada V, Daniels SR, et al.  Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2006;114(24):2710–2738. doi: 10.1161/CIRCULATIONAHA.106.179568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.179568</ArticleId>
            <ArticleId IdType="pubmed">17130340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beiser AS, Takahashi M, Baker AL, Sundel RP, Newburger JW. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol. 1998;81(9):1116–1120. doi: 10.1016/s0002-9149(98)00116-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0002-9149(98)00116-7</ArticleId>
            <ArticleId IdType="pubmed">9605052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>• Royal College of Paediatrics and Child Health Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19. 2020. A newly described Kawasaki-like disease associated with an infectious trigger. May help further support an infectious agent as the trigger in Kawasaki disease. Further studies are underway.</Citation>
        </Reference>
        <Reference>
          <Citation>• Riphagen S, Gomez X, Gonzales-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020. Advance online publication, 10.1016/S0140-6736(20)31094A newly described Kawasaki-like disease associated with an infectious trigger. May help further support an infectious agent as the trigger in Kawasaki disease</Citation>
        </Reference>
        <Reference>
          <Citation>• Verdoni L, Mazza A, Gervasoni A, Martelli L, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020. Advance online publication, 10.1016/S0140-6736(20)31103-XA newly described Kawasaki-like disease associated with an infectious trigger. Largest cohort to date. May help further support an infectious agent as the trigger in Kawasaki disease.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7220177</ArticleId>
            <ArticleId IdType="pubmed">32410760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Belhadjer Z, Méot M, Bajolle F, et al.  Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation. 2020;382:1370–1322. doi: 10.1161/CIRCULATIONAHA.120.048360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.048360</ArticleId>
            <ArticleId IdType="pubmed">32418446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>• Toubiana J, Poirault C, Corsia A, et al. Outbreak of Kawasaki disease in children during COVID-19 pandemic: a prospective observational study in Paris, France. medRxiv. Preprint posted. 2020. 10.1101/2020.05.10.20097394Emerging data on this new entitiy from France.</Citation>
        </Reference>
        <Reference>
          <Citation>• Centers for Disease Control and Prevention Health Alert Network (HAN). Multisystem inflammatory syndrome in children (MIS-C) associated with Coronavirus Disease 2019 (COVID-19). Available at: https://emergency.cdc.gov/han/2020/han00432.asp. Accessed on June 12,2020 The first clinical criteria formulated for this new Kawasaki-like entity.</Citation>
        </Reference>
        <Reference>
          <Citation>Wu MH, Chen HC, Yeh SJ, et al.  Prevalence and the long-term coronary risks of patients with Kawasaki disease in a general population &lt;40 years: a national database study. Circ Cardiovasc Qual Outcomes. 2012;5:566–570. doi: 10.1161/CIRCOUTCOMES.112.965194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCOUTCOMES.112.965194</ArticleId>
            <ArticleId IdType="pubmed">22589296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP, Shulman ST, Wiggins JW, Hicks RV, Fulton DR, Lewis AB, Leung DYM, Colton T, Rosen FS, Melish ME. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315(6):341–347. doi: 10.1056/NEJM198608073150601.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM198608073150601</ArticleId>
            <ArticleId IdType="pubmed">2426590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Levison ME, Pallasch TJ, Falace DA, Taubert KA, Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association  Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the Young, American Heart Association. Pediatrics. 2004;114(6):1708–1733. doi: 10.1542/peds.2004-2182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2004-2182</ArticleId>
            <ArticleId IdType="pubmed">15574639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori M, Miyamae T, Imagawa T, Katakura S, Kimura K, Yokota S. Meta-analysis of the results of intravenous gamma globulin treatment of coronary artery lesions in Kawasaki disease. Mod Rheumatol. 2004;14(5):361–366. doi: 10.1007/s10165-004-0324-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10165-004-0324-3</ArticleId>
            <ArticleId IdType="pubmed">17143694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashouri N, Takahashi M, Dorey F, Mason W. Risk factors for nonresponse to therapy in Kawasaki disease. J Pediatr. 2008;153(3):365–368. doi: 10.1016/j.jpeds.2008.03.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpeds.2008.03.014</ArticleId>
            <ArticleId IdType="pubmed">18534243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Chen Y, Tang Y, et al.  Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases. Eur J Pediatr. 2018;177(8):1279–1292. doi: 10.1007/s00431-018-3182-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00431-018-3182-2</ArticleId>
            <ArticleId IdType="pmc">PMC6061038</ArticleId>
            <ArticleId IdType="pubmed">29948255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng X, Yue P, Liu L, et al.  Efficacy between low and high dose aspirin for the initial treatment of Kawasaki disease: current evidence based on a meta-analysis. PLoS One. 2019;14(5):e0217274. doi: 10.1371/journal.pone.0217274.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0217274</ArticleId>
            <ArticleId IdType="pmc">PMC6531010</ArticleId>
            <ArticleId IdType="pubmed">31117119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baumer JH, Love SJ, Gupta A, Haines LC, Maconochie I, Dua JS. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2006;4:CD004175. doi: 10.1002/14651858.CD004175.pub2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD004175.pub2</ArticleId>
            <ArticleId IdType="pubmed">17054199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S, Dong Y, Kiuchi MG, Wang J, Li R, Ling Z, Zhou T, Wang Z, Martinek M, Pürerfellner H, Liu S, Krucoff MW. Coronary artery complication in Kawasaki disease and the importance of early intervention: a systematic review and meta-analysis. JAMA Pediatr. 2016;170:1156–1163. doi: 10.1001/jamapediatrics.2016.2055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamapediatrics.2016.2055</ArticleId>
            <ArticleId IdType="pubmed">27749951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wardle AJ, Connolly GM, Seager MJ, Tulloh RM. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2017;1:CD011188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6464937</ArticleId>
            <ArticleId IdType="pubmed">28129459</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, Atz AM, Li JS, Takahashi M, Baker AL, Colan SD, Mitchell PD, Klein GL, Sundel RP, Pediatric Heart Network Investigators  Pediatric heart network investigators. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007;356(7):663–675. doi: 10.1056/NEJMoa061235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa061235</ArticleId>
            <ArticleId IdType="pubmed">17301297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr. 2003;142:611–616. doi: 10.1067/mpd.2003.191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1067/mpd.2003.191</ArticleId>
            <ArticleId IdType="pubmed">12838187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, Takeuchi K, Morikawa A. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr. 2006;149:336–341. doi: 10.1016/j.jpeds.2006.05.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpeds.2006.05.025</ArticleId>
            <ArticleId IdType="pubmed">16939743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE study group investigators  Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379:1613–1620. doi: 10.1016/S0140-6736(11)61930-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(11)61930-2</ArticleId>
            <ArticleId IdType="pubmed">22405251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart. 2013;99(2):76–82. doi: 10.1136/heartjnl-2012-302126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/heartjnl-2012-302126</ArticleId>
            <ArticleId IdType="pubmed">22869678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimura M, Harazaki M, Fukuoka T, Asakura I, Sakai H, Kamimaki T, Ohkawara I, Akiyama N, Tsurui S, Iwashima S, Shimomura M, Morishita H, Meguro T, Seto S. Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease. Pediatr Int. 2017;59:397–403. doi: 10.1111/ped.13190.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ped.13190</ArticleId>
            <ArticleId IdType="pubmed">27743415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leung DY, Geha RS, Newburger JW, Burns JC, Fiers W, Lapierre LA, Pober JS. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J Exp Med. 1986;164(6):1958–1972. doi: 10.1084/jem.164.6.1958.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.164.6.1958</ArticleId>
            <ArticleId IdType="pmc">PMC2188474</ArticleId>
            <ArticleId IdType="pubmed">3491174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, Kanegaye JT, Kovalchin JP, Printz BF, Ramilo O, Burns JC. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9930):1731–1738. doi: 10.1016/S0140-6736(13)62298-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(13)62298-9</ArticleId>
            <ArticleId IdType="pubmed">24572997</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Son MB, Gauvreau K, Burns JC, et al.  Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011;158(4):644–649.e1. doi: 10.1016/j.jpeds.2010.10.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpeds.2010.10.012</ArticleId>
            <ArticleId IdType="pubmed">21129756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Portman MA, Dahdah NS, Slee A, et al.  Etanercept with IVIG for acute Kawasaki disease: a randomized controlled trial. Pediatrics. 2019;143(6):e20183675. doi: 10.1542/peds.2018-3675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2018-3675</ArticleId>
            <ArticleId IdType="pmc">PMC6564061</ArticleId>
            <ArticleId IdType="pubmed">31048415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen S, Tacke CE, Straver B, Meijer N, Kuipers IM, Kuijpers TW. A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation. Ann Rheum Dis. 2012;71(12):2059–2061. doi: 10.1136/annrheumdis-2012-201658.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2012-201658</ArticleId>
            <ArticleId IdType="pubmed">22689319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shafferman A, Birmingham JD, Cron RQ. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report. Pediatr Rheumatol Online J. 2014;12:26. doi: 10.1186/1546-0096-12-26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1546-0096-12-26</ArticleId>
            <ArticleId IdType="pmc">PMC4103976</ArticleId>
            <ArticleId IdType="pubmed">25045337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kone-Paut I, Cimaz R, Herberg J, Bates O, Carbasse A, Saulnier JP, Maggio MC, Anton J, Piram M. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: a retrospective cases series. Autoimmun Rev. 2018;17(8):768–774. doi: 10.1016/j.autrev.2018.01.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2018.01.024</ArticleId>
            <ArticleId IdType="pubmed">29885546</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>• Hamada H, Suzuki H, Onouchi Y, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial [published correction appears in Lancet. 2019 Mar 30;393(10178):1298] [published correction appears in Lancet. 2019 Apr 13;393(10180):1504]. Lancet. 2019;393(10176):1128–1137. 10.1016/S0140-6736(18)32003-8A promising study that adds a potential beneficial adjunctive primary therapy option in high-risk patients with Kawasaki disease. This study also demonstrated a good safety profile for Cyclosporine use.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30853151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okada S, Azuma Y, Suzuki Y, Yamada H, Wakabayashi-Takahara M, Korenaga Y, Akase H, Hasegawa S, Ohga S. Adjunct cyclosporine therapy for refractory Kawasaki disease in a very young infant. Pediatr Int. 2016;58(4):295–298. doi: 10.1111/ped.12778.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/ped.12778</ArticleId>
            <ArticleId IdType="pubmed">26670024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tremoulet AH, Pancoast P, Franco A, et al.  Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2012;161(3):506–512.e1. doi: 10.1016/j.jpeds.2012.02.048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpeds.2012.02.048</ArticleId>
            <ArticleId IdType="pmc">PMC3613150</ArticleId>
            <ArticleId IdType="pubmed">22484354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hokosaki T, Mori M, Nishizawa T, Nakamura T, Imagawa T, Iwamoto M, Yokota S. Long-term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatr Int. 2012;54(1):99–103. doi: 10.1111/j.1442-200X.2011.03487.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1442-200X.2011.03487.x</ArticleId>
            <ArticleId IdType="pubmed">22004042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sauvaget E, Bonello B, David M, Chabrol B, Dubus JC, Bosdure E. Resistant Kawasaki disease treated with anti-CD20. J Pediatr. 2012;160(5):875–876. doi: 10.1016/j.jpeds.2012.01.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpeds.2012.01.018</ArticleId>
            <ArticleId IdType="pubmed">22341587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee TJ, Kim KH, Chun JK, Kim DS. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J. 2008;49(5):714–718. doi: 10.3349/ymj.2008.49.5.714.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3349/ymj.2008.49.5.714</ArticleId>
            <ArticleId IdType="pmc">PMC2615375</ArticleId>
            <ArticleId IdType="pubmed">18972590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nozawa T, Imagawa T, Ito S. Coronary-artery aneurysm in tocilizumab-treated children with Kawasaki disease. N Engl J Med. 2017;377(19):1894–1896. doi: 10.1056/NEJMc1709609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1709609</ArticleId>
            <ArticleId IdType="pubmed">29117496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tremoulet AH, Jain S, Jone PN, et al.  Phase I/IIa trial of atorvastatin in patients with acute Kawasaki disease with coronary Aartery aneurysm. J Pediatr. 2019;215:107–117.e12. doi: 10.1016/j.jpeds.2019.07.064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpeds.2019.07.064</ArticleId>
            <ArticleId IdType="pmc">PMC6878161</ArticleId>
            <ArticleId IdType="pubmed">31561960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang SM, Weng KP, Chang JS, Lee WY, Huang SH, Hsieh KS. Effects of statin therapy in children complicated with coronary arterial abnormality late after Kawasaki disease: a pilot study. Circ J. 2008;72(10):1583–1587. doi: 10.1253/circj.cj-08-0121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1253/circj.cj-08-0121</ArticleId>
            <ArticleId IdType="pubmed">18758088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayasaka S, Nakamura Y, Yashiro M, Uehara R, Oki I, Tajimi M, Ojima T, Terai M, Yanagawa H. Analysis of fatal cases of Kawasaki disease in Japan using vital statistical data over 27 years. J Epidemiol. 2003;13:246–250. doi: 10.2188/jea.13.246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2188/jea.13.246</ArticleId>
            <ArticleId IdType="pubmed">14604219</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
